Cannasat Therapeutics Appoints George Nomikos as Senior Director, Scientific Affairs
MarketWire, October 30, 2021
TORONTO – Cannasat Therapeutics (TSXV: CTH) (the "Company"), the developer of novel cannabinoid-based pharmaceutical products, today announced that George Nomikos, former Scientific Director at Amgen, Inc. has been appointed as Senior Director, Scientific Affairs. Dr. Nomikos has published more than 140 papers in the field of Neuroscience, Neuropsychopharmacology and Cannabinoid Therapeutics, and brings invaluable knowledge and experience to the Cannasat drug development team.
From May 2006 to October 2007, Dr. Nomikos served as Senior Principal Scientist and Scientific Director, Neuroscience, at Amgen, Inc. based in Cambridge, Massachusetts. Prior to joining Amgen, from 1998 to 2006, he held positions of Senior Biologist, Research Scientist, and Principal Research Scientist, Neuroscience Discovery, at Eli Lilly & Company based in Indianapolis, Indiana. In 1997, Dr. Nomikos became Associate Professor of Pharmacology at Karolinska Institute, Stockholm, and in 2004 was elected Associate Professor in Pharmacology, Department of Pharmacology, Medical School, University of Athens, Athens. Dr. Nomikos has a Ph.D. (Neuroscience), from the University of British Columbia, Vancouver, British Columbia, and an M.D. from the Medical School, University of Athens, Athens.
Dr. Nomikos research interests include: discovery and development of medicines for the treatment of neuropsychiatric disorders; neuropsychopharmacology of affective/cognitive disorders and substance dependence; neurobiology of nicotine dependence; mesolimbocortical dopaminergic systems: role in hedonic homeostasis; cholinergic neurotransmission in the brain: integration of emotion and cognition; cannabinoid targets for drug discovery and development; and novel target identification and validation of therapeutic indications in neuropsychiatry.
"We are extremely pleased that George has joined our team,” said David Hill, Cannasat’s Chief Executive Officer. “He is one of the world’s preeminent cannabinoid researchers, has experience with both early stage and developed companies, and has a wealth of important contacts in both the pharmaceutical and academic research communities. This addition reflects the Company's ongoing commitment to enhance our intellectual property positions and to add knowledge and depth to our scientific team. George is a proven scientist who will make valuable contributions to both our existing drug programs, including our lead product CAT 310, as well as new products we intend to develop in our pipeline.”
About Cannasat Therapeutics
Founded in 2004, Cannasat is an early stage pharmaceutical research and development company. Cannasat is developing cannabinoid-based pharmaceutical products using proprietary formulation and drug delivery technologies. Cannabinoids have broad therapeutic applications which are believed to include the treatment of neuropathic pain, chronic pain, depression, anxiety and movement disorders. More information about Cannasat (TSX-V: CTH) is available at www.cannasat.com.
Contact Information
Cannasat Therapeutics Inc.
Andrew Williams
Chief Operating Officer
W: (416) 703-2449 (Ext. 253)
F: (416) 703-8752
[email protected]
www.cannasat.com
The TSX Venture Exchange Inc. has not reviewed and does not accept responsibility for the adequacy or accuracy of this press
